The blurred lines of Chronic hepatitis B
Date: Thu, 13 Oct 2022Time: 5.30-7pmLocation: Hybrid Event | Perrin LT, Whitechapel | MS TeamsRegistration: Eventbrite
An estimated 300 million people globally have chronic hepatitis B (CHB). It is the leading cause of primary liver cancer worldwide and the complications of chronic infection account for 800,000 deaths per year. There is currently no curative therapy for CHB, so the mainstay of treatment is continuous life-long viral suppression. A better understanding of the disease and the “disease phases” is a key factor in determining treatment candidacy and the success of future therapies. I will discuss our portfolio of work at QMUL in redefining CHB, changing treatment thresholds and clinical trials of novel therapeutic approaches to achieve functional cure.
Speaker bioProfessor Kennedy was born in Nenagh, Co.Tipperary and studied medicine at University College Dublin. He moved to Kings College Hospital for his post-graduate medical training in 1998 before completing his clinical training in Gastroenterology & Hepatology in London. He completed his Doctor of Medicine degree in HBV immunology at The Institute of Hepatology, UCL in 2006 and was awarded a HEFCE Clinical Senior Lectureship in 2009, leading to his appointment at Barts and The London School of Medicine and Dentistry.
Register
This is a hybrid event with guests able to attend in person or online.
5.30pm - Welcome by Prof Sir Mark Caulfield
5.05pm - The blurred lines of Chronic hepatitis B - Inaugural lecture by Professor Patrick Kennedy
6.20pm - Reception